Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

@article{Jones2010EfficacyAS,
  title={Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.},
  author={Peter Hadley Jones and Anne C. Goldberg and Howard R. Knapp and Maureen T. Kelly and Carolyn M. Setze and James C. Stolzenbach and Darryl J. Sleep},
  journal={American heart journal},
  year={2010},
  volume={160 4},
  pages={
          759-66
        }
}
BACKGROUND Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia. METHODS In this phase 3, multicenter, double-blind study, a total of 543 patients with triglycerides ≥150 mg/dL and <400 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40 mg/dL (<50 mg/dL for women), and LDL-C ≥130 mg/dL were randomized to 12 weeks of treatment with fenofibric acid 135 mg… Expand
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease
TLDR
The fenofibrate/pravastatin plus ezetimibe therapy improves the global atherogenic lipid profile in type 2 diabetic patients with mixed hyperlipidaemia. Expand
Ezetimibe therapy for dyslipidemia: an update.
TLDR
The results of the ongoing IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) which compares ezetimibe plus simVastatin with simvastatin monotherapy with regard to CVD outcomes after acute coronary syndromes should further elucidate the effect of ezETimibe on CVD events. Expand
Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
TLDR
Bezafibrate in combination with ezetimibe is safe and effective, and is potentially useful for comprehensive management of dyslipidemia. Expand
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
TLDR
The overall efficacy and subgroup’s efficacy of combination therapy of Ezetimibe and Atorvastatin on lowering LDL-C, TC and TG was significantly better than AtorVastatin monotherapy's and the overall and the E10 + A10/A20 group”s effectiveness of combination Therapy on rasing HDL-C were significantly significant. Expand
Comparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia : a meta-analysis
Objective: To compare adverse events of statin monotherapy and combination therapy of statin and fenofibrate. Methods: We searched the online databases of PUBMED and EMBASE for high-qualityExpand
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
TLDR
The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing. Expand
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism
TLDR
For patients who cannot tolerate statins there are useful combinations of ezetimibe with other drugs affecting lipid metabolism, which improve many metabolic parameters, but more trials should be carried out to reach more robust conclusions about their effects on cardiovascular disease prevention. Expand
Fenofibric acid for hyperlipidemia
TLDR
The current status of fenofibric acid in the management of dyslipidemia, especially in combination with statins, is discussed, and the comparative efficacy and safety profile of this new molecule against other agents in its class is addressed. Expand
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
TLDR
The present review presents the available data regarding the effects of statin/fibrate combination in patients with T2DM and atherogenic mixed dyslipidemia. Expand
The Effects of Atorvastatin Therapy on Rheological Characteristics of Erythrocyte Membrane, Serum Lipid Profile and Oxidative Status in Patients with Dyslipidemia
TLDR
The use of atorvastatin reversed the structural and functional features of erythrocyte membranes in dyslipidemic subjects and hypolipidemic therapy had a beneficial impact on a balance between oxidant and antioxidant systems. Expand
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
TLDR
ABT-335 + atorvastatin combination therapy resulted in more effective control of multiple lipid parameters than either monotherapy and may be an appropriate therapy for patients with mixed dyslipidemia. Expand
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
TLDR
Coadministration of EZE/SIMVA + FENO effectively improved the overall atherogenic lipid profile of patients with mixed hyperlipidemia. Expand
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
TLDR
For patients with mixed dyslipidemia, combination therapy provided more effective control of multiple lipid parameters than either monotherapy alone, with a safety profile similar to both monotherapies. Expand
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
TLDR
In patients with mixed dyslipidemia, combination therapy with ABT-335+rosuvastatin resulted in more effective control of multiple lipid parameters than either monotherapy alone, with a safety profile similar to both monotherapies. Expand
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
TLDR
Ezetimibe/simVastatin was more effective than atorvastatin in lowering LDL-C at each dose comparison and provided greater increases in HDL-C in statin doses at the 40- and 80-mg statin dose. Expand
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
TLDR
Long-term fenofibric acid + statin combination therapy was generally well tolerated and resulted in comprehensive and sustained improvements in multiple lipid parameters in adults with mixed dyslipidemia. Expand
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
TLDR
Long-term, 48-week co-administration of F ENO plus EZE was well tolerated and more efficacious than FENO in patients with mixed hyperlipidemia. Expand
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo‐controlled, blinded experience in 2382 patients with primary hypercholesterolemia
TLDR
Coadministration of ezetimibe’+ statin offers a well‐tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia and had a safety profile similar to statin monotherapy. Expand
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
TLDR
The pharmacologic properties of the fibrate drugs are evaluated, with particular attention to the effects of peroxisome proliferator activated receptor α activation in the control of dyslipidemia as well as in the attenuation of arterial inflammation. Expand
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
TLDR
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. Expand
...
1
2
3
...